EC Number |
Source Tissue |
Reference |
---|
3.4.17.20 | amniotic fluid |
TAFI amount in amniotic fluids of women with normal and complicated pregnancies, overview |
670949 |
3.4.17.20 | blood |
- |
670054, 670058, 700206, 754518, 754521 |
3.4.17.20 | blood |
the enzyme circulates as inactive zymogen in the blood stream becoming activated upon blood clotting |
668341 |
3.4.17.20 | blood plasma |
- |
647563, 651987, 653008, 653977, 667916, 668287, 668290, 670058, 670060, 670291, 670474, 670939, 670940, 670944, 696559, 696925, 696926, 697399, 697427, 697552, 697622, 697721, 697791, 698144, 698377, 699864, 699870, 700206, 701278, 701295, 707122, 707597, 709725, 709727, 754518 |
3.4.17.20 | blood plasma |
activity levels are higher in patients with acute myocardial infarction than in controls |
754511 |
3.4.17.20 | blood plasma |
CPU circulates in plasma as an inactive precursor, designated procarboxypeptidase U (proCPU or TAFI) from which it is released after activation by thrombin, plasmin, or the thrombin-thrombomodulin complex |
707113 |
3.4.17.20 | blood plasma |
in all individuals, carboxypeptidase U generation is biphasic. Marked inter-individual differences are present and a reference range is determined. The endogenous Carboxypeptidase U generation potential is the composite effect of multiple factors. With respect to the first carboxypeptidase U activity peak characteristics, a correlations with baseline proCPU concentration, proCPU Thr325Ile polymorphism, time to clot initiation and the clot lysis time is detected. The second CPU peak is related with baseline proCPU levels and with the maximum turbidity of the clot lysis profile |
755576 |
3.4.17.20 | blood plasma |
maternal and fetal |
670949 |
3.4.17.20 | blood plasma |
TAFI circulates at a concentration of 0.004-0.015 mg/ml |
653977 |
3.4.17.20 | blood platelet |
- |
670940 |